Standardized country-level delivery unit cost estimates for routine childhood, routine adolescent, and campaign vaccination: an updated modeling analysis

Allison Portnoy[1,2], Emma Clarke-Deelder[3,4], Taylor A. Holroyd[5], Daniel R. Hogan[5], Tewodaj Mengistu[5,*], Nicolas A. Menzies[2,6,*]

* *authors contributed equally.*

Affiliations: [1]Department of Global Health, Boston University School of Public Health; [2]Center for Health Decision Science, Harvard T.H. Chan School of Public Health; [3]Department of Research, Swiss Tropical & Public Health Institute; [4]University of Basel; [5]Gavi, the Vaccine Alliance; [6]Department of Global Health and Population, Harvard T.H. Chan School of Public Health.

Correspondence to: Allison Portnoy, Department of Global Health, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118. Email: aportnoy@bu.edu

Abstract

Background:

Reliable estimates of immunization delivery costs are essential for planning, budgeting, and economic evaluation of vaccination programs. Although a number of empirical costing studies have been conducted in recent years, many low- and middle-income countries (LMICs) continue to lack up-to-date, accurate delivery unit cost estimates—particularly for adolescent and campaign vaccination strategies. Building on prior work, this study aimed to produce updated, standardized country-level estimates of immunization delivery unit costs for different vaccination modalities across all LMICs.

Methods:

Using data on study-level unit cost estimates reported by empirical costing studies in the 2024 update of the Immunization Delivery Cost Catalogue, we fitted Bayesian meta-regression models predicting per-dose delivery costs for routine childhood vaccination, routine adolescent vaccination (using human papillomavirus vaccination as a proxy), and vaccination delivered via mass campaigns. Regression models incorporated country-level covariates (per-capita gross domestic product, population size, third-dose diphtheria-tetanus-pertussis vaccination coverage, urbanization, population density, and under-five mortality) and study-level characteristics (cost category, financial versus economic costing perspective, and full versus incremental costing methodology). Fitted models were used to generate country-specific and population-weighted average economic and financial cost per dose estimates for 2024, in 2024 US dollars.

Results:

The analysis included 142 observations for routine childhood vaccination, 63 observations for routine adolescent vaccination, and 113 observations for campaign vaccination. For 2024, the population-weighted mean economic cost per dose across all LMICs was estimated at $5.86 (95% uncertainty interval: $2.74–13.43) for routine childhood vaccination, $17.65 ($7.76–44.30) for routine adolescent vaccination, and $3.13 ($2.03–4.78) for campaign vaccination. Corresponding financial costs per dose were $3.02 ($1.52–6.29), $10.08 ($4.15–25.01), and $1.79 ($1.11–2.91), respectively. Substantial heterogeneity in delivery costs was observed across countries, delivery modalities, and cost perspectives. The estimated associations between predictors and unit costs may be influenced by unobserved study characteristics, and therefore should be interpreted as correlational rather than causal.

Conclusions:

By leveraging an expanded empirical evidence base and a Bayesian meta-regression framework, this study provides updated per-dose delivery costs for routine childhood vaccination and estimates new per-dose delivery costs for routine adolescent vaccination and campaign vaccination. As policy decisions often must be made despite incomplete information, these estimates provide a practical source of evidence to support analyses when direct cost data are unavailable.

1. Background

Routine immunization remains a cornerstone of primary health care and is recognized as a critical contributor to achieving 14 of the 17 Sustainable Development Goals (SDGs) adopted by countries in 2015 to "ensure prosperity for all" [1]. In the decade since, the global immunization landscape has been marked by a steady expansion in access to newer, higher-cost vaccines—especially pneumococcal conjugate vaccine (PCV) and rotavirus vaccine, and more recently a renewed push to scale up human papillomavirus (HPV) vaccination. In addition to routine services, preventive vaccination campaigns are periodically implemented to close immunity gaps (e.g., measles follow-up campaigns) or when introducing a vaccine to rapidly increase population-level immunity (e.g., measles–rubella catch-up campaigns). However, indicators of vaccine coverage have largely plateaued in recent years. For example, global third dose coverage of diphtheria-tetanus pertussis vaccine (DTP3) has varied around 85%, and measles coverage has not fully returned to pre-pandemic levels [2-4].

The Immunization Agenda 2030 (IA2030), launched in 2021, reaffirmed immunization as a key driver of health equity, pandemic preparedness, and sustainable development, while also emphasizing a life-course approach to vaccination that expands immunization beyond infancy to include adolescents and older age groups [5]. However, achieving the ambitions of IA2030 requires robust financial planning and reliable evidence on the full cost of delivering vaccines. This effort is even more relevant in today's challenging geopolitical and fiscal environment. Constrained public budgets, shifting donor priorities, and competing global health crises have tightened the resources available for immunization programs.

In this context, up-to-date cost estimates for vaccine delivery are essential to ensure that limited resources are allocated in ways that sustain equitable coverage and promote long-term program resilience [6, 7]. Such estimates can inform decisions about financial sustainability, enable efficiency analyses, and support applications for external assistance from mechanisms such as Gavi, the Vaccine Alliance. Moreover, delivery costs are often the dominant component of total immunization program expenditures, meaning that uncertainties in these estimates can significantly affect cost-effectiveness analyses and resource allocation decisions [8-10].

Despite notable progress—including the expansion of multi-country databases such as the Immunization Delivery Cost Catalogue (IDCC) [11]—evidence gaps persist. Many low- and middle-income countries (LMICs) still rely on outdated or non-representative cost data, limiting their ability to plan, budget, and evaluate immunization programs effectively. Continued investment in empirical costing studies remains critical to inform policy decisions and sustain the gains envisioned under IA2030. However, until locally-generated costing evidence becomes available for all countries, synthetic estimates extrapolated from other settings remain valuable for filling short-term evidence gaps.

The objective of this study was to update previously published estimates of standardized country-level delivery costs of vaccination for all LMICs [8] in three ways: (1) incorporating new data from the Immunization Delivery Cost Catalogue 2024 update [11]; (2) including outcomes for routine adolescent and campaign vaccine delivery; and (3) revising the estimation framework to adopt a more robust measure of model fit. Using the available study-level empirical data on per-dose delivery costs of vaccination, we fit a Bayesian meta-regression

model for routine childhood (i.e., under-five), routine adolescent (using HPV vaccine as a proxy), and campaign vaccination program delivery unit costs. We present estimates of delivery cost per dose across LMICs and by World Bank income level, by cost category (labor, supply chain, capital, and other service delivery costs), and by country.

2. Methods

We developed a Bayesian meta-regression model to predict vaccine delivery unit costs for routine childhood, routine adolescent, and campaign vaccinations (excluding vaccines and supplies such as syringes and safety boxes) in LMICs, according to World Bank country income classification in 2024 [12], updating a prior analysis [8]. In this section, we describe the data used to fit the model and the modeling methods.

2.1 Study data

We relied on a publicly available database describing immunization delivery costs in LMIC settings—the Immunization Delivery Cost Catalogue (IDCC) maintained by the Immunization Costing Action Network (ICAN) [9, 13]. The IDCC is an online web catalog and downloadable Excel spreadsheet of immunization delivery cost evidence in LMIC settings, which describes the results of a systematic review of published and grey literature (covering three categories of key words: “immunization” AND “cost” AND “delivery”) available between January 2005 and December 2023. The search of the peer-reviewed literature included six major electronic databases, including EconLit, Embase, Medline (via PubMed), NHS-EED, Web of Science, and WHO Global Index Medicus. Search terms included three categories of keywords—“immunization” AND “cost” AND delivery”—translated into the query language of each

database. All resources with full text availability in English, French, or Spanish, conducted in LMIC settings, that included a form of delivery unit cost data from primary data collection were included.

From the IDCC, we identified studies that reported delivery costs of routine (i.e., fixed facility) childhood vaccination (i.e., vaccines delivered up to age five), routine adolescent vaccination (using HPV vaccination as a proxy, including ages 9–15 and both school-based and facility-based delivery), and campaign vaccination. Delivery costs included labor, supply chain, capital, and other service delivery costs, and excluded costs related to the vaccine product, injection supplies, and wastage. "Labor" includes the costs of personnel administering vaccinations (as well as the value of volunteer labor for economic costs); "supply chain" includes costs for cold chain equipment, vehicles, transport, and fuel; "capital" includes either the annualized value of capital investments or the financial outlay for capital equipment for financial costs; and "other service delivery" includes costs for program management (i.e., supervision and monitoring), training, social mobilization, and disease surveillance [14]. We excluded studies that did not report a cost per dose, studies for which a cost per dose could not be calculated, and studies that did not define the cost categories included in the cost per dose. We also excluded studies that focused targeting vaccine delivery by factors other than age group or school year (i.e., high-risk populations) and studies that could not be categorized into either economic or financial costs.

For the identified studies, we extracted the study year, estimates of the delivery cost per dose, whether the vaccine was delivered through a campaign or routine delivery modality [$Routine$], whether the costing was for the full vaccination or incremental costs of adding a new antigen

[$Full$], and whether the presented costs were from the financial or economic perspective [$Econ$]. Financial costs refer to accounting transactions (i.e., expenditures or monetary outlays) whereas economic costs include both financial costs as well as the value of resources based on their opportunity cost, regardless of whether a financial transaction occurred (e.g., community outreach workers' volunteer labor) [15]. If any information reported in the IDCC was unclear for this analysis, we confirmed the information in the original studies. For the observed cost per dose outcome, we extracted the observation with the highest level of granularity available from a given study. For example, if the total vaccine delivery cost per dose were also reported as individual cost categories (i.e., labor, supply chain, capital, and other service delivery), we extracted the cost data for each component.

The IDCC 2024 update included delivery cost per dose estimates in 2022 US dollars. In order to present estimates in 2024 US dollars, the study values were inflated using local inflation according to the consumer price index and local currency-to-USD exchange rates [16, 17].

We compiled data on covariates potentially associated [8, 18] with immunization delivery unit costs: the year of data collection (*Year*), log gross domestic product (GDP) per capita (log(*GDP*)); reported diphtheria-tetanus-pertussis third dose coverage (*DTP3*); log under-five population (log(*Pop*)); log under-five mortality rate (log(*U5MR*)); log population density (log(*Density*)); and percentage urban population (*Urban*) [19, 20]. *DTP3* and *Urban* were included as continuous variables ranging from 0 (0% coverage) to 1 (100%) coverage. Model covariates were compiled for the year of data collection for each study. By using a log transformation of specified covariates, we assumed these explanatory factors relate to the

outcome on the multiplicative scale rather than linearly (for example, a doubling in per capita GDP produces a fixed increase in the outcome).

2.2 Prediction model

We used a Bayesian meta-regression model to regress immunization delivery unit costs against country-level and study-level explanatory variables (Table 1). Continuous variables ($Year$, log(*GDP*), *DTP3*, log(*Pop*), log(*U5MR*), log(*Density*), *Urban*) were standardized to mean zero and unit standard deviation before fitting the regression model. We adopted an analytic model that allowed the synthesis of cost estimates that included different combinations of cost categories. Under this approach, a regression equation with a separate cost intercept was specified for each of four cost categories, i.e., labor ($\hat{c}_i^l$), supply chain ($\hat{c}_i^{sc}$), service delivery ($\hat{c}_i^{sd}$), and capital ($\hat{c}_i^c$):

$$\hat{c}_i^l = \exp\,(\beta_{0_l} + \beta_1 * Econ_i + \beta_2 * Full_i + \beta_3 * Year_i + X_i\beta), \quad (1)$$

$$\hat{c}_i^{sc} = \exp\,(\beta_{0_{sc}} + \beta_1 * Econ_i + \beta_2 * Full_i + \beta_3 * Year_i + X_i\beta), \quad (2)$$

$$\hat{c}_i^{sd} = \exp\,(\beta_{0_{sd}} + \beta_1 * Econ_i + \beta_2 * Full_i + \beta_3 * Year_i + X_i\beta), \quad (3)$$

$$\hat{c}_i^c = \exp\,(\beta_{0_c} + \beta_1 * Econ_i + \beta_2 * Full_i + \beta_3 * Year_i + X_i\beta), \quad (4)$$

where $X_i\beta$ represents the set of covariates selected for inclusion based on model fit for routine childhood, routine adolescent, and campaign vaccine delivery for a given study i. Each regression equation included indicators for economic or financial costs ($Econ_i$) and full or incremental costing methodology ($Full_i$), and a covariate for study year ($Year_i$). An additional equation related these cost category unit costs to the combination of cost categories included in each empirical study estimate, with tc_i representing the mean estimate of the delivery cost per dose for a given study i:

$$tc_i = \hat{c}_i^l * I_l + \hat{c}_i^{sc} * I_{sc} + \hat{c}_i^{sd} * I_{sd} + \hat{c}_i^c * I_c \quad (5)$$

We constructed a prediction model for the intervention cost per dose outcome, specified as a generalized linear regression model (GLM), assuming a Gamma distributed outcome and a log link function. In addition to study-level predictors, we selected country-level covariates according to the best fit model using minimized Watanabe-Akaike Information Criterion (WAIC). The model specification assumed a Gamma likelihood function for the observed data y_i where the shape parameter α described the residual variance:

$$y_i \sim Gamma(\alpha, \frac{\alpha}{c_i}) \quad (6)$$

This specification assumed variance proportional to c_i. We assumed informative prior distributions for all regression coefficients, which were assumed to follow a normal distribution centered at zero with a standard deviation of 1 [21]. The shape parameter was assumed to follow a half-Cauchy distribution centered at zero with a standard deviation of 5 [22].

The prediction model was estimated in R software, version 4.4.1, using an adaptive Hamiltonian Monte Carlo algorithm in the Stan software package, version 2.32.6, with four chains of 5000 iterations. The first 2500 iterations were discarded, yielding 10,000 posterior draws for analysis [23]. Model diagnostics were examined to determine any problems encountered by the sampler, and the potential scale reduction factor (i.e., Rhat) for all parameters was evaluated to confirm that the model had successfully converged.

The fitted prediction model was used to generate both economic and financial cost per dose estimates for each LMIC for the year 2024. To generate these estimates, we predicted values from the fitted model, with covariate values specific to each country and year. Global cost per

dose estimates were calculated as averages weighted by the estimated under-five population of individual countries and further stratified by World Bank income level to produce cost per dose estimates for low-income, lower middle-income, and upper middle-income countries [12]. We tested predictive performance by comparing model predictions to the observed cost per dose matched to country and year of observation for the covariate values.

3. Results

3.1 Data

We identified 32 studies across 20 countries with delivery costs for routine childhood vaccines reported in the IDCC, from which including 141 observations were extracted and included in the analysis (Table 2). For routine HPV vaccination delivery, we identified 13 studies across 15 countries, from which 62 observations were extracted and included in the analysis. For campaign vaccination delivery, we identified 34 studies across 23 countries, from which 104 observations were extracted and included in the analysis. The majority of campaign studies represented single-antigen vaccine delivery, but 23% of the observations included integrated delivery of multiple vaccines or multiple vaccines alongside vitamin A supplementation and albendazole provision. Across studies, the observed cost per dose in 2024 USD ranged from $0.08 to $36.24(mean: $2.84), $0.36 to $20.51 (mean: $3.61), and $0.02 to $10.50 (mean: $1.90) for routine childhood, routine HPV, and campaign vaccine delivery, respectively.

3.2 Regression model

Table 3 reports point estimates and standard errors for regression coefficients and other model parameters. For routine childhood, the best fit model specification according to minimized

WAIC included covariates log(Pop), $DTP3$, and log($U5MR$). For routine adolescent vaccine delivery, the best fit model specification according to minimized WAIC included covariates log($Density$). For campaign vaccine delivery, the best fit model specification according to minimized WAIC included covariates log(GDP), log(Pop), $DTP3$, log($U5MR$) and log($Density$). Figure 1 displays the in-sample fit comparing observed versus predicted values for the study sample for each delivery modality.

3.3 Estimated costs per dose for all LMICs

For the year 2024, the population-weighted average economic cost per dose for routine delivery of childhood vaccines was estimated to be $5.86 (95% uncertainty interval: $2.74–13.43) across all 136 LMICs, whereas the population-weighted average financial cost per dose was estimated to be $3.02 ($1.52–6.29). The population-weighted average economic cost per dose for routine delivery of HPV vaccines was estimated to be $17.65 ($7.76–44.30), and the equivalent financial cost per dose was estimated to be $10.08 ($4.15–25.01). Finally, for vaccines delivered via mass vaccination campaign, the population-weighted average economic cost per dose was estimated to be $3.13 ($2.03–4.78) and the population-weighted average financial cost per dose was estimated to be $1.79 ($1.11–2.91). The set of country-specific estimates for delivery cost per dose can be found in Appendix Table A.

By income level, the population-weighted mean economic cost per dose for routine childhood vaccine delivery was: $8.97 ($2.16–30.68) for low-income countries; $4.39 ($2.38–8.41) for lower-middle income countries; and $6.46 ($3.46–11.96) for upper-middle income countries. For routine adolescent vaccine delivery, the equivalent estimates were: $19.15 ($8.46–48.08) for

low-income countries; $16.59 ($7.09–41.93) for lower-middle income countries; and $18.61 ($8.24–46.50) for upper-middle income countries. For campaign vaccine delivery, the equivalent cost estimates were: $5.91 ($3.35–10.14) for low-income countries; $2.46 ($1.57–3.83) for lower-middle income countries; and $2.45 ($1.25–4.44) for upper-middle income countries.

4. Discussion

For the year 2024, the average economic cost per dose across all LMICs for routine delivery of childhood vaccines was estimated to be $5.86 ($2.74–13.43), excluding vaccine costs. The average financial cost per dose across all LMICs was and $3.02 ($1.52–6.29). For routine delivery of adolescent vaccines, the average economic cost per dose across all LMICs was estimated to be $17.65 ($7.76–44.30), and a corresponding financial cost per dose was estimated to be $10.08 ($4.15–25.01). For campaign vaccine delivery, the average economic cost per dose was estimated to be $3.13 ($2.03–4.78), and a corresponding financial cost per dose was estimated to be $1.79 ($1.11–2.91).

Model-based estimation approaches, such as Bayesian meta-regression, can be practical and policy-relevant tools to support decision-making, particularly for countries lacking recent empirical data. Using observed costs per dose from the 2024 update of the IDCC, our study provides updated delivery cost estimates for 2024 and adds routine adolescent (using HPV vaccine as a proxy) and campaign vaccine delivery to our previous routine childhood delivery estimates. The meta-regression framework has broader applicability across other areas of global health where empirical cost data are limited, offering a replicable approach for generating timely, evidence-based cost inputs for economic evaluation and strategic planning. When compared to

the prior analysis [8] that the current study builds on, incorporating minimized WAIC for model selection and adding additional observations from the IDCC 2024 update appears to meaningfully change the delivery cost estimates. Inflating our earlier delivery cost estimates for economic costs of routine childhood vaccine delivery from 2018 USD to 2024 USD, our meta-regression relying on the IDCC 2019 update would be equivalent to $2.41 ($0.83–5.65) per dose.

Because the estimates presented in this study are population-weighted, the large number of observations from lower middle-income country settings contribute substantially to the overall averages. Although one might expect vaccine delivery costs to be lowest in low-income countries due to potentially lower input prices, these results suggest that costs per dose are shaped by multiple structural factors beyond price levels. Programs in middle-income countries often vaccinate substantially larger birth cohorts and achieve higher service volumes, allowing fixed logistical and programmatic costs to be spread across more doses. In contrast, immunization delivery in many low-income settings may rely more heavily on outreach services and need to overcome greater geographic dispersion, weaker infrastructure, and smaller service volumes, all of which can increase the resources required to deliver each dose. Middle-income settings may also benefit from stronger health system integration and more efficient supply chains, which can further reduce operational costs per dose despite higher input prices.

The meta-regression results (Table 2) highlight both the structural drivers of delivery costs and the differences across delivery platforms. Across the routine childhood, routine adolescent, and campaign model fits, the positive coefficient on the economic cost indicator suggests that studies

reporting economic (rather than purely financial) costs consistently produce higher unit cost estimates, as expected given the inclusion of opportunity costs such as personnel time and capital depreciation. By contrast, the “full cost” indicator indicates variable effects across modalities, indicating that the incremental inclusion of broader cost categories did not translate uniformly into higher per-dose estimates and may reflect heterogeneity in how “full” costs are defined across studies.

For routine childhood immunization, negative associations with population size, DTP3 coverage, and under-five mortality are broadly consistent with expectations. Larger populations and higher coverage levels likely reflect greater economies of scale and more established service delivery systems, reducing average delivery costs per dose. The negative association with under-five mortality may similarly capture stronger health system infrastructure in lower-mortality settings. These findings align with the conceptual expectation that mature, high-performing routine programs operate more efficiently on a per-dose basis.

For routine adolescent delivery (proxied by HPV vaccination), the relationship with population density was modestly negative. This suggests that unit delivery costs tend to be lower in more densely populated settings. This pattern is plausible given that adolescent vaccination programs—particularly those delivered through schools or targeted outreach campaigns—may benefit from geographic concentration of the target population, reducing logistical complexity and per-dose service delivery costs. In contrast, delivering vaccines to adolescents in sparsely populated areas may require greater outreach effort to reach smaller and more dispersed cohorts. The absence of strong scale-related predictors such as population in this model, relative to

routine childhood delivery, may reflect the distinct structure of adolescent programs, which often rely on targeted outreach to specific age cohorts rather than routine service delivery to infants through established primary care platforms.

Campaign delivery exhibits the strongest associations with the best fit model predictors. The negative coefficients on GDP per capita, population size, population density, and under-five mortality suggest that campaign costs per dose are higher in smaller, lower-density, lower-income, and higher-mortality settings, i.e., contexts where logistical challenges, transport costs, and weaker infrastructure likely increase operational complexity. This is consistent with the expectation that campaigns are particularly sensitive to geographic dispersion and system fragility. Compared with routine childhood delivery, campaign costs appear more strongly shaped by contextual and structural determinants, whereas routine platforms benefit more from embedded health system capacity and scale. Although the mean estimated cost per dose for campaigns appears lower than for routine delivery, this finding should be interpreted cautiously. Many of the underlying costing studies do include start-up or introduction activities—such as planning, training, and micro-planning—but the extent to which these costs are comprehensively captured varies across studies, and some preparatory activities (e.g., broader programmatic planning, development of social mobilization strategies, or investments in cold chain and logistics) may not always be fully attributed to the campaign delivery episode in reported estimates. As a result, some important costs associated with launching or preparing campaigns may be underrepresented in the underlying observations. Moreover, campaigns typically target substantially larger populations over a short time horizon; when total delivery costs are considered at the scale of the full target population, and when any omitted start-up or preparation

costs are taken into account, the overall resource requirements for campaigns may exceed those associated with routine immunization delivered annually through established health systems.

Taken together, these patterns are directionally consistent with theoretical expectations. Routine childhood immunization appears to realize economies of scale and performance-related efficiencies, adolescent delivery reflects a hybrid model influenced by broader system capacity but less strongly by traditional scale variables, and campaigns are highly sensitive to contextual constraints. These differences underscore that delivery modality is not merely an operational distinction but a structural determinant of cost behavior, with implications for projecting the financial requirements of expanding immunization programs.

There are several limitations to this analysis, many of which are inherent to the underlying body of costing evidence and therefore persist in this updated analysis. First, the direction and magnitude of the coefficients in the model could be driven by unobserved characteristics of the included studies (e.g., the costs of inputs, or the data collection approach) that are correlated with both the predictor variables and the unit cost. For this reason, all of these relationships should be viewed as correlations with the predicted cost per dose and should not be interpreted causally. For example, Figure 1 illustrates that the routine childhood vaccine model fit reproduces the central tendency of observed delivery costs but does not fully capture the dispersion in the underlying data. Predicted costs are compressed within a relatively narrow range, whereas observed estimates span several orders of magnitude on the log scale. As a result, lower observed costs tend to be overpredicted and higher observed costs underpredicted. This pattern suggests

regression-based shrinkage toward the mean and indicates that the covariates included in the meta-regression do not fully explain cross-study and cross-country heterogeneity. Consequently, while the meta-regression provides smoothed and internally consistent estimates suitable for comparative analysis, predicted values for settings with unusually low or high delivery costs—such as remote, fragile, or small-population contexts—should be interpreted with caution. Additionally, the studies included in the dataset differed substantially in scope, costing methods, and reporting practices. Prior systematic reviews have documented similar variation in immunization costing methodologies [10, 24-27]. Although we employed a modeling strategy designed to accommodate differences in reported cost categories and distinctions between financial and economic costs, this did not eliminate all cross-study inconsistencies. As a result, the relatively large residual variance in the meta-regression likely captures not only sampling variability but also non-sampling error attributable to methodological heterogeneity. All studies were conducted from the immunization provider perspective and excluded caregiver time and transportation costs; however, the operationalization of this perspective may have differed across settings. While we standardized cost categories to improve comparability, variation likely remains, particularly in the treatment of capital or investment costs (e.g., assumed useful life, discounting, and annuitization).

A second limitation is that the analysis assumes that vaccine delivery costs do not vary systematically by vaccine product. This simplifying assumption was necessitated by the way cost data were reported in primary studies. In practice, delivery costs may differ by product characteristics—for example, injectable versus oral vaccines, differences in required training or cold chain handling, or the extent to which multiple antigens are co-administered during a single

visit. This is particularly relevant to the estimated costs of campaign vaccine delivery; twelve of 34 studies (35%) of campaign vaccine delivery describe the costs of mass vaccination with oral cholera vaccine, potentially resulting in lower estimated costs per dose of campaign vaccination relative to routine vaccination than might be expected.

Third, although this meta-regression incorporates a relatively large number of studies, most primary studies included only a limited number of service delivery sites. Estimates derived from small samples may not fully capture within-country heterogeneity, particularly where facility-level variation is substantial [59]. Moreover, the countries represented in each analytic dataset do not constitute a representative sample of all LMICs. While the regression models adjust for observable country characteristics, limited overlap between the sampled countries and the full population increases uncertainty for settings whose covariate profiles fall outside the observed range.

Finally, in estimating delivery costs for routine adolescent immunization, we relied on available data from HPV vaccination programs as a proxy. While HPV vaccination represents the most widely implemented routine adolescent vaccine platform in many LMICs, delivery strategies for HPV vaccination—often school-based or campaign-style approaches targeting specific age cohorts—may differ from those used for other adolescent vaccines delivered through facility-based services or integrated primary care platforms (including but not limited to meningococcal conjugate vaccine and tetanus-diphtheria-pertussis booster). HPV programs in most LMICs only target females, who may be more expensive to reach on average than males, given lower school

enrollment rates among girls. Differences in target population, outreach requirements, community mobilization, and service integration could result in systematic differences in delivery costs.

This study cannot fully address the persistent evidence gap resulting from the small number of published immunization costing studies—particularly given the breadth of settings and policy questions where such information is needed. The modeled estimates presented here inevitably reflect the constraints and assumptions of the underlying empirical data. Continued investment in primary data collection on immunization delivery costs remains essential to strengthen the evidence base for immunization program planning and decision-making. Nonetheless, policy decisions often must be made despite incomplete information, and these modeled estimates provide a practical and transparent source of evidence to support analyses when direct cost data are unavailable.

These updated cost-per-dose estimates continue to provide a valuable resource for cost-effectiveness analyses and economic evaluations in settings where empirical cost data are unavailable, outdated, or uncertain. As countries increasingly seek to use evidence-based approaches for immunization program planning and budgeting, modeled delivery cost estimates can serve as an important complementary source of information—particularly as empirical immunization cost data remain sparse for many delivery strategies and vaccines.

Acknowledgements

The authors thank Kelsey Vaughan, Christian Suharlim, Stephen C. Resch, and Logan Brenzel for their collaboration and support on the previous analysis that this work builds on.

Author contributions

AP conceptualized and designed the updated study that builds on a previous study conceptualized and designed by AP and NAM. AP did the analysis, drafted the initial manuscript, and approved the final manuscript as submitted. ECD, TAH, DRH, TM, and NAM developed the methodology, critically reviewed the analysis, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Availability of data and materials

The data that support the findings of this study are openly available in the Immunization Delivery Cost Catalogue (IDCC) at https://immunizationeconomics.org/ican-idcc/. All data produced in the present work are contained in the manuscript and supplementary materials.

Funding

This work was supported by Gavi, the Vaccine Alliance (GAVI100001260).

Conflict of interest

The authors, Allison Portnoy, Emma Clarke-Deelder, Taylor A. Holroyd, Daniel R. Hogan, Tewodaj Mengistu, and Nicolas A. Menzies, declare that they have no competing interests.

Code availability

The programming code is available from the corresponding author on reasonable request.

References

1. United Nations. Sustainable development goals (SDGs). Geneva: United Nations; 2015. Last updated: September 2015. [Online] Accessed 12 February 2018. Available at: http://www.un.org/sustainabledevelopment/sustainable-development-goals/. 2015.
2. World Health Organization. WHO-UNICEF estimates of DTP3 coverage: monitoring system 2024 global summary. Last updated: 15 Jul 2025. [Online] Accessed 18 Sep 2025. Available at: https://immunizationdata.who.int/global
3. World Health Organization. The Big Catch-Up: An Essential Immunization Recovery Plan for 2023 and Beyond. Last Updated; 26 July 2023. [Online] Accessed 6 June 2025. Available at: https://www.who.int/publications/i/item/9789240075511.
4. Hartner AM, Li X, Echeverria-Londono S, Roth J, Abbas K, Auzenbergs M, et al. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study. Lancet Glob Health. 2024;12(4):e563-e71.
5. World Health Organization. Immunization Agenda 2030: a global strategy to leave no one behind. Last updated: 1 April 2020. [Online] Accessed 6 June 2025. Available at: https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind.
6. Hargreaves JR, Greenwood B, Clift C, Goel A, Roemer-Mahler A, Smith R, et al. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines. Lancet (London, England). 2011;378(9806):1885-93.
7. Brenzel L. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries? Vaccine. 2015;33 Suppl 1:A93-8.
8. Portnoy A, Vaughan K, Clarke-Deelder E, Suharlim C, Resch SC, Brenzel L, et al. Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates. Pharmacoeconomics. 2020;38(9):995-1005.
9. Vaughan K, Ozaltin A, Mallow M, Moi F, Wilkason C, Stone J, et al. The costs of delivering vaccines in low- and middle-income countries: Findings from a systematic review. Vaccine X. 2019;2:100034.
10. Munk C, Portnoy A, Suharlim C, Clarke-Deelder E, Brenzel L, Resch SC, et al. Systematic review of the costs and effectiveness of interventions to increase infant vaccination coverage in low- and middle-income countries. BMC Health Serv Res. 2019;19(1):741.
11. Immunization Costing Action Network (ICAN). Immunization delivery cost catalogue (IDCC). ThinkWell. Last updated: 20 Jun 2024. [Online] Accessed 28 Sep 2024. Available at: https://immunizationeconomics.org/thinkwell-idcc/
12. World Bank. World Bank Country and Lending Groups. Washington, DC: The World Bank. Last updated: 1 July 2025. [Online] Accessed 18 Sep 2025. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519.
13. Immunization Costing Action Network (ICAN). Immunization delivery cost catalogue (IDCC). ThinkWell. Last updated: 20 Jun 2024. [Online] Accessed 20 Jun 2024. Available at: https://immunizationeconomics.org/thinkwell-idcc/
14. Brenzel L, Young D, Walker DG. Costs and financing of routine immunization: Approach and selected findings of a multi-country study (EPIC). Vaccine. 2015;33 Suppl 1:A13-20.

15. Resch S, Menzies NA, Portnoy A, Clarke-Deelder E, O'Keeffe L, Suharlim C, et al. HOW TO COST IMMUNIZATION PROGRAMS: A Practical Guide on Primary Data Collection and Analysis. December 2020. [Online] Accessed 17 Feb 2026. Available at: https://immunizationeconomics.org/recent-activity/2020/12/23/how-to-cost-guide/.
16. World Bank. World development indicators. Last updated: 1 Jul 2025. [Online] Accessed 18 Sep 2025. Available at: https://data.worldbank.org/
17. International Monetary Fund. World economic outlook database. April 2025. [Online] Accessed 24 Sept 2025. Available at: https://www.imf.org/en/publications/weo/weo-database/2025/april.
18. UNICEF. Costs of Fully Vaccinating a Child. August 2024. [Online] Accessed 25 September 2025. Available at: https://www.unicef.org/documents/costs-fully-vaccinating-child.
19. World Bank. World development indicators. Washington, DC: The World Bank; 2019. Last updated: 10 July 2019. [Online] Accessed 13 August 2019. Available at: http://data.worldbank.org/. 2019.
20. World Health Organization. WHO-UNICEF estimates of DTP3 coverage: monitoring system 2019 global summary. Geneva: WHO/UNICEF. Last updated: 15 July 2019. [Online] Accessed 13 August 2019. Available at: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html. 2019.
21. Gelman A. Prior Choice Recommendations. Last updated: 27 April 2025. [Online] Accessed 25 May 2025. Available at: https://github.com/stan-dev/stan/wiki/Prior-Choice-Recommendations.
22. Gelman A. Prior distributions for variance parameters in hierarchical models. Bayesian Analysis. 2006;1(3):515 - 34.
23. Hoffman MD, Gelman A. The No-U-Turn Sampler: Adaptively Setting Path Lengths in Hamiltonian Monte Carlo. Journal Of Machine Learning Research. 2014;15:1593-623.
24. Batt K, Fox-Rushby JA, Castillo-Riquelme M. The costs, effects and cost-effectiveness of strategies to increase coverage of routine immunizations in low- and middle-income countries: systematic review of the grey literature. Bull World Health Organ. 2004;82(9):689-96.
25. Clarke-Deelder E, Vassall A, Menzies NA. Estimators Used in Multisite Healthcare Costing Studies in Low- and Middle-Income Countries: A Systematic Review and Simulation Study. Value Health. 2019;22(10):1146-53.
26. Ozawa S, Yemeke TT, Thompson KM. Systematic review of the incremental costs of interventions that increase immunization coverage. Vaccine. 2018;36(25):3641-9.
27. Pegurri E, Fox-Rushby JA, Walker DG. The effects and costs of expanding the coverage of immunisation services in developing countries: a systematic literature review. Vaccine. 2004;23(13):1624-35.

Table 1. Model covariates, prior to model fitting.

Covariate name	Description
Labor indicator (I_l)	Labor cost category included in cost per dose=1; otherwise=0
Supply chain indicator (I_{sc})	Supply chain cost category included in cost per dose=1; otherwise=0
Service delivery indicator (I_{sd})	Service delivery cost category included in cost per dose=1; otherwise=0
Capital indicator (I_c)	Capital cost category included in cost per dose=1; otherwise=0
Econ	Cost type: financial=0; economic=1; undefined=2
Full	Costing included full vaccine program=1; incremental antigen=0
log(*GDP*)	GDP per capita in study year, logged
DTP3	DTP3 coverage in study year
log(*Pop*)	Under-five country population size in study year, logged
log(*U5MR*)	Under-five deaths per 1000 live births, logged
log(*Density*)	People per square kilometer of country land area, logged
Urban	Percentage of the country population living in urban areas

Note: Model covariates matched to study year for the included studies, prior to model fitting. DTP3 = diphtheria-tetanus-pertussis third dose coverage; GDP = gross domestic product; U5MR = under-five mortality rate.

Table 2. Summary characteristics for unit cost per dose observed data.

Variable	Routine childhood vaccine delivery	Routine adolescent vaccine delivery	Campaign vaccine delivery
	***n* of 141**	***n* of 62**	***n* of 104**
Income			
• LI	21	15	51
• LMI	77	42	51
• UMI	43	3	2
Cost type			
• Economic	66	24	52
• Financial	75	38	52
Costing approach			
• Full	78	26	76
• Incremental	63	36	28
	Average (Minimum–Maximum) across observed data		
Per-capita gross domestic product	$1970 ($305–8016)	$1756 ($565–6406)	$1560 ($400–7983)
Under-five population (thousands)	18532 (59–119616)	8283 (64–129882)	17215 (1115–128478)
Third dose coverage of diphtheria-tetanus-pertussis vaccine	89% (73–99%)	88% (68–99%)	84% (53–98%)
Under-five mortality rate	46 (11–154)	51 (7–127)	70 (21–137)
Population density	139 (18–476)	146 (4–518)	259 (15–1301)
Percentage urban population	39% (17–71%)	31% (16–76%)	39% (16–75%)

Note: LI = low-income; LMI = lower middle-income; SIA = supplementary immunization activities; UMI = upper middle-income.

Table 3. Mean coefficient and standard errors for regressions of delivery unit cost per dose on predictors by delivery modality.

Variable	Routine childhood	Routine adolescent	Campaign
Cost category intercepts			
Labor	0.0382 (0.0073)	0.3204 (0.0030)	-1.2920 (0.0086)
Supply chain	-1.1603 (0.0090)	-0.5691 (0.0069)	-1.2992 (0.0088)
Service delivery	-1.3743 (0.0064)	-0.5853 (0.0072)	-0.1348 (0.0077)
Capital	-1.0230 (0.0081)	0.0037 (0.0086)	-1.0055 (0.0074)
Predictors			
Economic cost indicator	0.6461 (0.0018)	0.5660 (0.0021)	0.5662 (0.0017)
Full cost indicator	-0.0324 (0.0021)	-0.0947 (0.0020)	-0.5441 (0.0020)
Year	-0.0690 (0.0012)	0.3337 (0.0010)	-0.0964 (0.0008)
log(GDP per capita)	Excluded*	Excluded*	-0.4924 (0.0014)
log(population)	-0.1269 (0.0010)	Excluded*	-0.1462 (0.0018)
DTP3 coverage	-0.2031 (0.0014)	Excluded*	-0.0855 (0.0016)
log(U5MR)	-0.4024 (0.0012)	Excluded*	-0.9217 (0.0016)
log(Density)	Excluded*	-0.1321 (0.0009)	-0.4327 (0.0020)
Urban	Excluded*	Excluded*	Excluded*
Gamma dispersion parameter			
Alpha	1.1948 (0.0012)	1.8387 (0.0031)	1.4094 (0.0020)

*Covariate excluded as part of the selection of best fit model for this cost outcome.

Note: Continuous predictors were standardized to mean zero and unit standard deviation; thus, fitted coefficients for continuous variables (e.g., log(doses)) represent the increase in log cost per dose observed for a 1.0 standard deviation increase in the variable. Values in parentheses represent standard errors. DTP3 = diphtheria-tetanus-pertussis third dose coverage; GDP = gross domestic product; U5MR = under-five mortality rate.

Figure 1. Comparison of predicted cost per dose and published literature cost per dose.
(A) Routine Childhood Vaccine Delivery



(B) Routine Adolescent (HPV) Vaccine Delivery



(C) Campaign Vaccine Delivery



Appendix Table A. Predicted immunization delivery cost per dose in 2024 by delivery modality and country.

Country	Income	Region	Economic Cost of Childhood Vaccine Delivery	Financial Cots of Childhood Vaccine Delivery	Economic Cost of Adolescent Vaccine Delivery	Financial Cost of Adolescent Vaccine Delivery	Economic Cost of Campaign Vaccine Delivery	Financial Cost of Campaign Vaccine Delivery
Afghanistan	LI	EMR	$10.94 ($2.21–35.08)	$5.52 ($1.28–16.11)	$19.08 ($8.44–47.82)	$10.90 ($4.50–27.13)	$9.97 ($4.89–18.71)	$5.69 ($2.69–11.10)
Albania	UMI	EUR	$7.10 ($3.12–14.13)	$3.72 ($1.63–7.38)	$18.08 ($7.97–45.39)	$10.33 ($4.28–25.65)	$4.10 ($1.27–10.14)	$2.33 ($0.71–5.80)
Algeria	UMI	AFR	$5.04 ($2.85–8.39)	$2.64 ($1.51–4.36)	$21.89 ($9.29–55.80)	$12.51 ($5.01–31.32)	$3.21 ($1.72–5.61)	$1.83 ($0.95–3.31)
Angola	LMI	AFR	$7.58 ($1.97–21.76)	$3.86 ($1.13–10.05)	$20.87 ($9.02–53.22)	$11.92 ($4.86–29.77)	$2.40 ($1.34–4.05)	$1.37 ($0.73–2.43)
Argentina	UMI	AMR	$12.62 ($4.15–30.67)	$6.46 ($2.37–14.52)	$22.27 ($9.38–56.98)	$12.73 ($5.04–32.10)	$2.94 ($1.15–6.44)	$1.68 ($0.63–3.76)
Armenia	UMI	EUR	$7.69 ($3.35–15.31)	$4.02 ($1.77–7.85)	$18.03 ($7.94–45.21)	$10.30 ($4.26–25.56)	$4.48 ($1.45–10.73)	$2.55 ($0.81–6.19)
Azerbaijan	UMI	EUR	$39.43 ($3.76–169.27)	$19.54 ($2.16–77.73)	$17.72 ($7.79–44.33)	$10.12 ($4.17–25.09)	$4.93 ($1.12–14.91)	$2.81 ($0.62–8.60)
Bangladesh	LMI	SEAR	$3.34 ($1.96–5.55)	$1.77 ($0.95–3.06)	$14.07 ($5.01–37.10)	$8.03 ($2.76–21.78)	$0.66 ($0.35–1.21)	$0.38 ($0.19–0.71)
Belarus	UMI	EUR	$6.99 ($3.36–12.90)	$3.67 ($1.74–6.88)	$19.77 ($8.68–50.10)	$11.30 ($4.65–28.12)	$5.24 ($1.99–11.47)	$2.99 ($1.11–6.55)
Belize	UMI	AMR	$10.84 ($3.50–26.42)	$5.61 ($1.92–12.97)	$22.10 ($9.33–56.30)	$12.63 ($5.02–31.73)	$6.45 ($1.35–19.68)	$3.67 ($0.75–11.14)
Benin	LMI	AFR	$7.00 ($1.64–21.35)	$3.56 ($0.93–9.82)	$17.73 ($7.80–44.37)	$10.13 ($4.17–25.11)	$2.14 ($1.06–4.01)	$1.22 ($0.59–2.32)
Bhutan	LMI	SEAR	$6.12 ($2.42–13.17)	$3.22 ($1.25–6.96)	$21.71 ($9.26–55.49)	$12.41 ($4.99–31.12)	$7.21 ($1.99–18.80)	$4.10 ($1.13–10.69)
Bolivia	LMI	AMR	$22.64 ($3.53–80.33)	$11.36 ($2.03–37.17)	$23.39 ($9.54–60.55)	$13.37 ($5.18–34.09)	$6.27 ($2.20–14.40)	$3.58 ($1.22–8.53)
Bosnia and Herzegovina	UMI	EUR	$15.35 ($4.32–40.79)	$7.86 ($2.46–19.38)	$19.07 ($8.44–47.77)	$10.89 ($4.50–27.11)	$6.21 ($1.53–17.45)	$3.54 ($0.87–10.00)
Botswana	UMI	AFR	$4.40 ($2.03–8.60)	$2.31 ($1.05–4.59)	$26.44 ($9.89–69.62)	$15.11 ($5.32–39.73)	$2.23 ($0.87–4.83)	$1.27 ($0.48–2.74)
Brazil	UMI	AMR	$5.40 ($3.19–8.73)	$2.83 ($1.69–4.51)	$21.18 ($9.12–54.02)	$12.11 ($4.90–30.27)	$2.33 ($1.08–4.51)	$1.33 ($0.60–2.67)
Burkina Faso	LI	AFR	$2.24 ($1.14–4.28)	$1.18 ($0.57–2.29)	$18.50 ($8.17–46.33)	$10.57 ($4.37–26.18)	$2.37 ($1.51–3.65)	$1.35 ($0.83–2.18)
Burundi	LI	AFR	$3.89 ($2.01–7.08)	$2.03 ($1.06–3.67)	$15.31 ($6.10–39.30)	$8.74 ($3.29–22.49)	$12.84 ($4.22–30.46)	$7.31 ($2.42–17.26)
Cabo Verde	UMI	AFR	$9.02 ($3.28–20.56)	$4.70 ($1.74–10.29)	$17.62 ($7.74–44.14)	$10.07 ($4.14–24.99)	$7.48 ($1.73–21.62)	$4.26 ($0.97–12.20)
Cambodia	LMI	WPR	$7.57 ($3.34–15.45)	$3.92 ($1.86–7.39)	$18.16 ($8.01–45.58)	$10.38 ($4.31–25.76)	$5.77 ($3.10–9.99)	$3.29 ($1.73–5.85)
Cameroon	LMI	AFR	$4.30 ($1.80–9.18)	$2.22 ($0.99–4.42)	$19.22 ($8.49–48.32)	$10.98 ($4.52–27.30)	$2.26 ($1.45–3.40)	$1.29 ($0.80–2.04)
Central African Republic	LI	AFR	$17.01 ($1.32–79.97)	$8.42 ($0.78–36.30)	$24.32 ($9.64–63.62)	$13.90 ($5.26–35.69)	$5.03 ($1.54–12.72)	$2.88 ($0.84–7.31)
Chad	LI	AFR	$3.67 ($1.13–9.65)	$1.89 ($0.62–4.61)	$22.61 ($9.45–58.00)	$12.92 ($5.08–32.78)	$1.56 ($0.91–2.57)	$0.89 ($0.50–1.53)
China	UMI	WPR	$4.47 ($2.65–7.12)	$2.35 ($1.34–3.91)	$17.34 ($7.60–43.61)	$9.90 ($4.06–24.76)	$1.75 ($0.65–3.92)	$1.00 ($0.36–2.30)
Colombia	UMI	AMR	$6.77 ($3.55–11.90)	$3.53 ($1.94–5.98)	$19.71 ($8.66–49.90)	$11.26 ($4.64–28.02)	$3.37 ($1.69–6.18)	$1.92 ($0.93–3.61)
Comoros	LMI	AFR	$10.50 ($2.76–29.45)	$5.37 ($1.55–13.89)	$15.53 ($6.29–39.52)	$8.87 ($3.40–22.80)	$4.87 ($1.26–13.17)	$2.78 ($0.71–7.55)
Congo	LMI	AFR	$7.42 ($2.71–17.35)	$3.82 ($1.52–8.23)	$22.10 ($9.33–56.30)	$12.63 ($5.02–31.73)	$4.69 ($2.31–8.69)	$2.68 ($1.28–5.07)
Congo DR	LI	AFR	$5.59 ($1.69–14.67)	$2.85 ($0.95–6.82)	$19.79 ($8.69–50.09)	$11.31 ($4.65–28.15)	$3.79 ($2.31–6.27)	$2.17 ($1.25–3.75)
Cote d'Ivoire	LMI	AFR	$4.28 ($1.81–9.14)	$2.22 ($1.00–4.39)	$18.20 ($8.02–45.65)	$10.40 ($4.32–25.80)	$1.58 ($0.94–2.55)	$0.90 ($0.52–1.52)
Cuba	UMI	AMR	$6.01 ($2.98–11.06)	$3.16 ($1.53–5.89)	$17.99 ($7.92–45.17)	$10.28 ($4.26–25.44)	$3.55 ($1.42–7.60)	$2.02 ($0.79–4.30)
Djibouti	LMI	EMR	$8.09 ($2.31–21.60)	$4.16 ($1.30–10.24)	$19.60 ($8.63–49.60)	$11.20 ($4.61–27.80)	$3.67 ($1.09–9.36)	$2.09 ($0.62–5.28)
Dominica	UMI	AMR	$8.81 ($2.29–24.38)	$4.58 ($1.23–12.14)	$18.34 ($8.09–45.91)	$10.48 ($4.35–25.93)	$4.04 ($0.45–15.98)	$2.29 ($0.26–8.89)
Dominican Republic	UMI	AMR	$5.97 ($2.80–11.56)	$3.11 ($1.53–5.75)	$16.57 ($7.07–41.94)	$9.46 ($3.82–23.58)	$1.47 ($0.60–3.12)	$0.84 ($0.33–1.83)
Ecuador	UMI	AMR	$15.83 ($4.04–44.43)	$8.04 ($2.30–20.76)	$18.78 ($8.32–47.06)	$10.73 ($4.43–26.62)	$4.60 ($1.79–10.00)	$2.63 ($0.98–5.93)

Egypt	LMI	EMR	$4.23 ($2.50–6.86)	$2.23 ($1.25–3.76)	$17.87 ($7.88–44.83)	$10.21 ($4.23–25.32)	$4.12 ($2.17–7.23)	$2.35 ($1.20–4.32)
El Salvador	UMI	AMR	$6.69 ($3.23–12.32)	$3.50 ($1.71–6.46)	$16.14 ($6.76–40.80)	$9.22 ($3.64–23.35)	$3.89 ($1.62–8.05)	$2.22 ($0.91–4.60)
Equatorial Guinea	UMI	AFR	$7.88 ($1.81–24.22)	$4.02 ($1.02–11.15)	$19.01 ($8.43–47.61)	$10.86 ($4.48–26.96)	$1.29 ($0.35–3.51)	$0.73 ($0.19–2.06)
Eritrea	LI	AFR	$4.51 ($2.17–8.54)	$2.37 ($1.13–4.53)	$20.90 ($9.02–53.41)	$11.94 ($4.87–29.83)	$13.32 ($5.32–28.01)	$7.58 ($3.03–16.01)
Ethiopia	LI	AFR	$6.50 ($2.33–15.18)	$3.37 ($1.29–7.33)	$18.81 ($8.34–47.15)	$10.74 ($4.44–26.68)	$3.43 ($1.15–8.13)	$1.95 ($0.65–4.61)
Fiji	UMI	WPR	$6.19 ($2.46–13.74)	$3.18 ($1.38–6.43)	$17.91 ($7.90–44.95)	$10.23 ($4.24–25.32)	$4.91 ($3.07–7.80)	$2.81 ($1.66–4.73)
Gabon	UMI	AFR	$6.08 ($2.46–12.84)	$3.18 ($1.30–6.67)	$19.54 ($8.62–49.47)	$11.17 ($4.60–27.73)	$3.92 ($1.19–9.88)	$2.23 ($0.66–5.63)
Gambia	LI	AFR	$19.90 ($3.11–72.36)	$10.01 ($1.78–33.06)	$23.89 ($9.62–61.93)	$13.66 ($5.23–34.84)	$3.48 ($0.85–10.00)	$1.99 ($0.47–5.74)
Georgia	UMI	EUR	$7.01 ($2.51–16.40)	$3.62 ($1.40–7.86)	$16.39 ($6.95–41.49)	$9.36 ($3.75–23.49)	$7.08 ($2.82–14.88)	$4.04 ($1.59–8.62)
Ghana	LMI	AFR	$10.24 ($3.90–22.70)	$5.30 ($2.16–11.02)	$18.99 ($8.42–47.58)	$10.85 ($4.48–26.89)	$4.69 ($1.47–11.55)	$2.67 ($0.83–6.66)
Grenada	UMI	AMR	$3.61 ($2.05–6.18)	$1.90 ($1.03–3.33)	$17.40 ($7.62–43.81)	$9.94 ($4.07–24.79)	$3.25 ($1.96–5.15)	$1.85 ($1.08–3.05)
Guatemala	UMI	AMR	$9.68 ($2.88–24.78)	$5.04 ($1.52–12.58)	$15.94 ($6.58–40.41)	$9.10 ($3.56–23.12)	$3.68 ($0.45–13.96)	$2.09 ($0.26–7.90)
Guinea	LMI	AFR	$8.38 ($3.46–17.90)	$4.32 ($1.95–8.41)	$17.16 ($7.46–43.29)	$9.80 ($4.01–24.50)	$3.02 ($1.46–5.63)	$1.73 ($0.81–3.32)
Guinea-Bissau	LI	AFR	$5.28 ($1.28–15.73)	$2.69 ($0.72–7.40)	$19.26 ($8.51–48.49)	$11.01 ($4.53–27.35)	$1.33 ($0.63–2.53)	$0.76 ($0.34–1.50)
Haiti	LMI	AMR	$7.92 ($1.84–24.02)	$4.04 ($1.04–11.09)	$18.69 ($8.28–46.77)	$10.68 ($4.41–26.49)	$4.96 ($1.83–10.93)	$2.83 ($1.03–6.29)
Honduras	LMI	AMR	$12.48 ($2.28–42.58)	$6.30 ($1.30–19.36)	$15.64 ($6.36–39.85)	$8.93 ($3.44–22.86)	$2.35 ($0.86–5.44)	$1.34 ($0.47–3.16)
India	LMI	SEAR	$12.46 ($3.86–31.39)	$6.37 ($2.21–14.84)	$18.24 ($8.05–45.72)	$10.42 ($4.32–25.82)	$6.70 ($2.96–13.42)	$3.83 ($1.65–7.78)
Indonesia	UMI	SEAR	$3.32 ($1.99–5.31)	$1.75 ($0.99–2.91)	$15.43 ($6.19–39.48)	$8.81 ($3.36–22.60)	$1.83 ($0.80–3.76)	$1.05 ($0.44–2.21)
Iran	UMI	EMR	$7.64 ($3.40–15.39)	$3.94 ($1.94–7.22)	$17.38 ($7.61–43.74)	$9.93 ($4.06–24.79)	$2.87 ($1.63–4.86)	$1.64 ($0.88–2.91)
Iraq	UMI	EMR	$4.73 ($2.72–7.77)	$2.49 ($1.37–4.27)	$19.34 ($8.53–48.74)	$11.05 ($4.55–27.44)	$4.27 ($2.23–7.62)	$2.44 ($1.21–4.53)
Jamaica	UMI	AMR	$5.29 ($2.95–8.89)	$2.76 ($1.58–4.56)	$18.08 ($7.97–45.39)	$10.33 ($4.28–25.64)	$2.65 ($1.45–4.55)	$1.52 ($0.80–2.69)
Jordan	LMI	EMR	$5.58 ($2.52–11.09)	$2.94 ($1.28–5.93)	$16.38 ($6.94–41.44)	$9.35 ($3.74–23.46)	$3.09 ($1.07–7.20)	$1.76 ($0.59–4.08)
Kazakhstan	UMI	EUR	$5.71 ($2.99–9.95)	$3.00 ($1.56–5.32)	$17.66 ($7.76–44.18)	$10.09 ($4.15–25.01)	$4.65 ($2.31–8.49)	$2.65 ($1.29–4.91)
Kenya	LMI	AFR	$5.36 ($2.93–9.14)	$2.82 ($1.50–4.95)	$24.63 ($9.69–64.76)	$14.08 ($5.27–36.23)	$2.55 ($1.08–5.18)	$1.45 ($0.60–3.03)
Kiribati	LMI	WPR	$3.79 ($2.18–6.39)	$1.99 ($1.13–3.34)	$18.21 ($8.03–45.66)	$10.40 ($4.32–25.81)	$3.34 ($2.04–5.27)	$1.91 ($1.12–3.17)
Korea DPR	LI	SEAR	$4.74 ($1.56–11.51)	$2.48 ($0.82–6.02)	$17.22 ($7.52–43.41)	$9.83 ($4.03–24.60)	$4.38 ($0.98–12.72)	$2.49 ($0.56–7.20)
Kyrgyz Republic	LMI	EUR	$4.62 ($2.48–8.08)	$2.44 ($1.25–4.42)	$16.68 ($7.15–42.16)	$9.53 ($3.86–23.64)	$7.89 ($3.86–14.38)	$4.49 ($2.18–8.38)
Lao PDR	LMI	WPR	$8.35 ($3.56–17.34)	$4.32 ($1.98–8.35)	$20.29 ($8.88–51.25)	$11.59 ($4.74–29.02)	$8.64 ($3.93–16.86)	$4.92 ($2.21–9.71)
Lebanon	LMI	EMR	$12.38 ($2.88–37.42)	$6.29 ($1.63–17.21)	$20.53 ($8.94–52.02)	$11.73 ($4.78–29.32)	$6.03 ($2.46–12.63)	$3.44 ($1.38–7.29)
Lesotho	LMI	AFR	$46.15 ($3.80–207.18)	$22.80 ($2.17–96.04)	$15.20 ($6.01–39.10)	$8.68 ($3.25–22.46)	$5.25 ($0.96–17.23)	$3.00 ($0.53–10.06)
Liberia	LI	AFR	$4.52 ($1.82–9.73)	$2.36 ($0.98–4.95)	$18.68 ($8.27–46.77)	$10.67 ($4.41–26.47)	$5.68 ($2.46–11.34)	$3.23 ($1.39–6.52)
Libya	UMI	EMR	$3.66 ($1.52–7.70)	$1.91 ($0.82–3.91)	$19.32 ($8.52–48.72)	$11.04 ($4.54–27.40)	$3.88 ($2.14–6.52)	$2.21 ($1.21–3.81)
North Macedonia	UMI	EUR	$6.53 ($2.87–13.28)	$3.39 ($1.58–6.56)	$26.60 ($9.90–69.79)	$15.21 ($5.32–40.11)	$3.15 ($1.36–6.36)	$1.80 ($0.75–3.70)
Madagascar	LI	AFR	$9.26 ($1.96–29.51)	$4.68 ($1.13–13.59)	$19.46 ($8.58–49.12)	$11.12 ($4.57–27.54)	$6.55 ($3.43–11.72)	$3.74 ($1.89–6.93)
Malawi	LI	AFR	$4.17 ($2.29–7.27)	$2.19 ($1.19–3.77)	$16.68 ($7.15–42.18)	$9.53 ($3.86–23.64)	$9.72 ($4.53–18.43)	$5.54 ($2.57–10.73)
Malaysia	UMI	WPR	$6.50 ($3.49–11.16)	$3.40 ($1.86–5.76)	$18.01 ($7.93–45.15)	$10.29 ($4.26–25.49)	$2.67 ($1.21–5.23)	$1.52 ($0.67–3.03)
Maldives	UMI	SEAR	$8.17 ($3.08–17.92)	$4.29 ($1.60–9.38)	$13.71 ($4.70–36.49)	$7.82 ($2.59–21.28)	$0.63 ($0.06–2.66)	$0.36 ($0.04–1.50)

Mali	LI	AFR	$2.43 ($1.12–4.93)	$1.27 ($0.59–2.53)	$21.92 ($9.30–55.88)	$12.53 ($5.00–31.35)	$1.70 ($1.10–2.60)	$0.97 ($0.61–1.54)
Marshall Islands	UMI	WPR	$11.92 ($2.81–34.58)	$6.15 ($1.54–16.98)	$16.65 ($7.13–42.08)	$9.51 ($3.85–23.66)	$5.41 ($0.58–21.92)	$3.08 ($0.33–12.19)
Mauritania	LMI	AFR	$5.71 ($2.57–11.42)	$2.97 ($1.41–5.67)	$26.11 ($9.86–69.16)	$14.93 ($5.32–39.08)	$5.55 ($2.83–9.93)	$3.16 ($1.59–5.78)
Mauritius	UMI	AFR	$8.14 ($3.14–17.92)	$4.25 ($1.66–8.97)	$15.03 ($5.88–38.46)	$8.58 ($3.17–22.36)	$1.87 ($0.39–5.78)	$1.06 ($0.22–3.25)
Mexico	UMI	AMR	$9.37 ($3.88–19.77)	$4.82 ($2.21–9.28)	$18.95 ($8.41–47.51)	$10.83 ($4.47–26.88)	$2.09 ($0.91–4.20)	$1.19 ($0.50–2.48)
Micronesia	LMI	WPR	$16.97 ($3.40–54.33)	$8.65 ($1.92–25.63)	$17.23 ($7.53–43.39)	$9.84 ($4.03–24.60)	$9.20 ($1.24–33.95)	$5.24 ($0.70–19.01)
Moldova	UMI	EUR	$9.64 ($3.60–21.69)	$4.99 ($1.98–10.45)	$18.36 ($8.11–45.94)	$10.49 ($4.35–25.97)	$4.66 ($1.43–11.62)	$2.65 ($0.81–6.66)
Mongolia	UMI	WPR	$6.33 ($3.00–11.86)	$3.32 ($1.58–6.28)	$28.95 ($9.98–77.99)	$16.55 ($5.35–44.93)	$4.90 ($1.92–10.46)	$2.79 ($1.08–6.01)
Montenegro	UMI	EUR	$17.06 ($4.42–46.95)	$8.74 ($2.50–22.61)	$19.75 ($8.68–49.99)	$11.28 ($4.64–28.08)	$6.63 ($1.13–22.28)	$3.77 ($0.64–12.72)
Morocco	LMI	EMR	$4.95 ($2.78–8.31)	$2.60 ($1.43–4.44)	$18.47 ($8.16–46.26)	$10.55 ($4.36–26.13)	$4.43 ($2.41–7.61)	$2.53 ($1.34–4.49)
Mozambique	LI	AFR	$6.12 ($2.04–15.16)	$3.13 ($1.14–7.08)	$19.98 ($8.76–50.52)	$11.42 ($4.68–28.50)	$5.73 ($3.45–9.21)	$3.27 ($1.89–5.55)
Myanmar	LMI	SEAR	$8.78 ($2.81–22.05)	$4.49 ($1.59–10.29)	$18.50 ($8.17–46.32)	$10.57 ($4.37–26.18)	$6.05 ($3.54–9.90)	$3.46 ($1.95–5.92)
Namibia	LMI	AFR	$9.45 ($2.75–24.96)	$4.84 ($1.55–11.81)	$27.17 ($9.92–72.04)	$15.53 ($5.32–41.12)	$3.66 ($1.34–8.23)	$2.09 ($0.75–4.77)
Nepal	LMI	SEAR	$4.13 ($2.31–7.11)	$2.18 ($1.15–3.86)	$16.77 ($7.19–42.55)	$9.58 ($3.89–23.79)	$6.03 ($3.27–10.23)	$3.44 ($1.83–6.04)
Nicaragua	LMI	AMR	$7.73 ($3.56–15.06)	$4.02 ($1.92–7.48)	$19.31 ($8.52–48.69)	$11.03 ($4.54–27.40)	$8.21 ($3.65–16.31)	$4.68 ($2.05–9.32)
Niger	LI	AFR	$1.45 ($0.63–3.10)	$0.77 ($0.32–1.65)	$21.77 ($9.27–55.58)	$12.44 ($4.99–31.20)	$1.17 ($0.68–1.93)	$0.67 ($0.38–1.15)
Nigeria	LMI	AFR	$2.92 ($1.02–7.05)	$1.50 ($0.56–3.42)	$16.49 ($7.01–41.76)	$9.42 ($3.79–23.55)	$0.98 ($0.51–1.80)	$0.56 ($0.28–1.07)
Pakistan	LMI	EMR	$11.01 ($4.05–25.00)	$5.71 ($2.20–12.25)	$18.76 ($8.31–46.96)	$10.72 ($4.42–26.58)	$6.12 ($1.56–16.80)	$3.48 ($0.89–9.61)
Papua New Guinea	LMI	WPR	$2.86 ($1.66–4.83)	$1.50 ($0.86–2.51)	$16.07 ($6.70–40.64)	$9.18 ($3.62–23.23)	$1.76 ($0.99–3.01)	$1.01 ($0.55–1.81)
Paraguay	UMI	AMR	$40.82 ($2.75–196.52)	$20.06 ($1.57–88.39)	$21.46 ($9.19–54.99)	$12.27 ($4.95–30.69)	$5.63 ($1.46–15.69)	$3.22 ($0.80–9.12)
Peru	UMI	AMR	$10.35 ($3.73–23.95)	$5.33 ($2.10–11.39)	$22.19 ($9.35–56.66)	$12.68 ($5.03–31.92)	$4.69 ($1.86–10.09)	$2.68 ($1.03–5.83)
Philippines	LMI	WPR	$9.25 ($3.75–19.88)	$4.77 ($2.12–9.36)	$21.09 ($9.09–53.83)	$12.05 ($4.89–30.07)	$3.30 ($1.53–6.35)	$1.88 ($0.84–3.71)
Rwanda	LI	AFR	$9.94 ($3.27–24.49)	$5.08 ($1.87–11.42)	$15.77 ($6.45–40.07)	$9.01 ($3.50–23.02)	$2.35 ($1.32–4.00)	$1.34 ($0.72–2.42)
Samoa	UMI	WPR	$3.34 ($1.76–6.04)	$1.77 ($0.87–3.35)	$15.22 ($6.03–39.13)	$8.69 ($3.25–22.48)	$3.53 ($1.93–5.98)	$2.01 ($1.09–3.53)
Sao Tome and Principe	LMI	AFR	$11.93 ($3.49–30.85)	$6.15 ($1.93–15.07)	$18.62 ($8.25–46.62)	$10.64 ($4.40–26.37)	$8.63 ($1.69–27.11)	$4.91 ($0.95–15.10)
Senegal	LMI	AFR	$11.24 ($3.50–28.01)	$5.81 ($1.92–13.72)	$16.55 ($7.06–41.88)	$9.45 ($3.81–23.58)	$9.59 ($1.90–29.63)	$5.45 ($1.08–16.66)
Serbia	UMI	EUR	$4.24 ($2.29–7.48)	$2.22 ($1.19–3.89)	$18.28 ($8.07–45.83)	$10.44 ($4.33–25.89)	$4.64 ($2.75–7.43)	$2.64 ($1.54–4.38)
Sierra Leone	LI	AFR	$7.59 ($3.50–14.41)	$3.97 ($1.86–7.52)	$18.58 ($8.22–46.49)	$10.61 ($4.39–26.30)	$3.50 ($1.17–8.24)	$1.99 ($0.65–4.73)
Solomon Islands	LMI	WPR	$1.90 ($0.84–3.99)	$1.00 ($0.42–2.14)	$17.85 ($7.87–44.70)	$10.19 ($4.22–25.31)	$1.74 ($1.08–2.75)	$0.99 ($0.60–1.60)
Somalia	LI	EMR	$8.88 ($3.24–20.38)	$4.60 ($1.78–9.84)	$20.92 ($9.03–53.51)	$11.96 ($4.87–29.89)	$11.41 ($3.37–28.58)	$6.49 ($1.92–16.20)
South Africa	UMI	AFR	$3.24 ($1.06–8.17)	$1.67 ($0.58–3.95)	$20.88 ($9.02–53.31)	$11.93 ($4.87–29.79)	$1.95 ($1.20–3.10)	$1.12 ($0.66–1.84)
South Sudan	LI	AFR	$8.04 ($2.94–18.66)	$4.13 ($1.66–8.66)	$19.50 ($8.59–49.24)	$11.14 ($4.59–27.63)	$2.24 ($1.15–4.05)	$1.28 ($0.62–2.41)
Sri Lanka	LMI	SEAR	$3.38 ($1.13–8.31)	$1.74 ($0.62–4.05)	$22.14 ($9.33–56.40)	$12.65 ($5.03–31.79)	$1.68 ($0.95–2.81)	$0.96 ($0.53–1.64)
St. Lucia	UMI	AMR	$6.00 ($3.23–10.29)	$3.15 ($1.68–5.49)	$15.87 ($6.54–40.23)	$9.06 ($3.53–23.13)	$3.99 ($2.08–7.08)	$2.27 ($1.15–4.14)
St. Vincent and the Grenadines	UMI	AMR	$7.80 ($2.60–18.52)	$4.09 ($1.35–9.72)	$16.19 ($6.81–41.03)	$9.25 ($3.66–23.41)	$3.27 ($0.49–11.54)	$1.86 ($0.28–6.48)
Sudan	LI	EMR	$8.86 ($2.79–21.81)	$4.64 ($1.46–11.32)	$16.38 ($6.94–41.46)	$9.35 ($3.75–23.47)	$4.93 ($0.65–18.26)	$2.80 ($0.37–10.18)

Suriname	UMI	AMR	$33.02 ($2.32–154.61)	$16.22 ($1.33–70.67)	$21.06 ($9.07–53.73)	$12.03 ($4.89–30.01)	$7.59 ($2.83–17.09)	$4.35 ($1.56–10.06)
Eswatini	LMI	AFR	$22.25 ($3.93–75.21)	$11.25 ($2.25–35.57)	$26.81 ($9.92–70.67)	$15.33 ($5.34–40.47)	$7.51 ($1.33–24.94)	$4.28 ($0.75–14.29)
Syrian Arab Republic	LI	EMR	$11.64 ($3.63–29.33)	$5.95 ($2.06–13.83)	$17.74 ($7.81–44.37)	$10.13 ($4.18–25.13)	$14.58 ($6.64–28.72)	$8.32 ($3.68–16.73)
Tajikistan	LMI	EUR	$4.35 ($2.31–7.74)	$2.29 ($1.17–4.17)	$18.74 ($8.30–46.88)	$10.70 ($4.42–26.55)	$8.19 ($4.06–14.78)	$4.67 ($2.29–8.64)
Tanzania	LMI	AFR	$4.96 ($2.57–8.97)	$2.58 ($1.42–4.39)	$18.74 ($8.30–46.91)	$10.71 ($4.42–26.56)	$5.63 ($3.38–9.03)	$3.22 ($1.85–5.42)
Thailand	UMI	SEAR	$6.43 ($3.50–10.92)	$3.36 ($1.87–5.64)	$17.47 ($7.67–43.91)	$9.98 ($4.09–24.86)	$3.35 ($1.71–6.03)	$1.91 ($0.95–3.51)
Timor-Leste	LMI	SEAR	$6.18 ($2.19–14.45)	$3.20 ($1.20–7.04)	$18.27 ($8.07–45.80)	$10.44 ($4.33–25.88)	$6.24 ($2.25–13.98)	$3.55 ($1.27–7.94)
Togo	LI	AFR	$3.39 ($1.68–6.36)	$1.78 ($0.88–3.34)	$17.15 ($7.45–43.27)	$9.79 ($4.01–24.50)	$3.80 ($2.27–6.09)	$2.17 ($1.27–3.56)
Tonga	UMI	WPR	$8.41 ($2.84–19.81)	$4.41 ($1.49–10.29)	$17.40 ($7.62–43.80)	$9.94 ($4.07–24.79)	$9.49 ($1.66–31.28)	$5.39 ($0.94–17.54)
Tunisia	LMI	EMR	$5.67 ($2.93–10.06)	$2.98 ($1.52–5.37)	$18.61 ($8.24–46.57)	$10.63 ($4.39–26.35)	$5.37 ($2.55–10.11)	$3.06 ($1.43–5.84)
Turkiye	UMI	EUR	$4.53 ($2.58–7.53)	$2.39 ($1.28–4.16)	$17.92 ($7.90–44.98)	$10.24 ($4.24–25.33)	$1.69 ($0.72–3.43)	$0.96 ($0.40–1.99)
Turkmenistan	UMI	EUR	$3.60 ($1.79–6.74)	$1.90 ($0.90–3.70)	$22.48 ($9.43–57.60)	$12.85 ($5.07–32.55)	$1.73 ($0.76–3.44)	$0.99 ($0.42–1.97)
Tuvalu	UMI	WPR	$11.10 ($2.65–31.81)	$5.78 ($1.39–16.20)	$15.99 ($6.63–40.51)	$9.13 ($3.58–23.11)	$7.97 ($0.61–36.19)	$4.52 ($0.34–19.77)
Uganda	LI	AFR	$3.81 ($2.21–6.40)	$2.00 ($1.15–3.35)	$16.55 ($7.06–41.88)	$9.45 ($3.81–23.58)	$4.77 ($2.78–7.79)	$2.72 ($1.53–4.62)
Ukraine	UMI	EUR	$8.21 ($3.90–15.68)	$4.27 ($2.13–7.70)	$18.81 ($8.34–47.15)	$10.75 ($4.44–26.68)	$5.41 ($2.57–10.22)	$3.09 ($1.42–5.93)
Uzbekistan	LMI	EUR	$6.28 ($3.41–10.73)	$3.28 ($1.85–5.48)	$18.58 ($8.22–46.49)	$10.61 ($4.39–26.30)	$5.82 ($3.28–9.73)	$3.32 ($1.81–5.79)
Vanuatu	LMI	WPR	$20.50 ($3.87–67.30)	$10.39 ($2.22–31.90)	$21.13 ($9.11–53.91)	$12.08 ($4.90–30.15)	$12.18 ($2.25–39.36)	$6.94 ($1.26–22.01)
Venezuela	UMI	AMR	$18.15 ($3.46–58.56)	$9.14 ($1.99–27.21)	$20.59 ($8.95–52.24)	$11.77 ($4.79–29.47)	$2.07 ($0.62–5.40)	$1.19 ($0.34–3.16)
Viet Nam	LMI	WPR	$4.23 ($2.46–6.97)	$2.23 ($1.23–3.81)	$16.06 ($6.69–40.65)	$9.17 ($3.61–23.22)	$2.35 ($1.36–3.88)	$1.34 ($0.76–2.31)
Yemen	LI	EMR	$34.63 ($2.71–157.40)	$17.05 ($1.55–71.66)	$18.76 ($8.31–46.98)	$10.72 ($4.42–26.59)	$17.77 ($6.15–41.90)	$10.17 ($3.39–24.35)
Zambia	LMI	AFR	$3.76 ($2.04–6.60)	$1.97 ($1.07–3.45)	$21.00 ($9.04–53.55)	$12.00 ($4.88–29.96)	$5.36 ($3.14–8.70)	$3.06 ($1.74–5.13)
Zimbabwe	LMI	AFR	$3.90 ($2.08–6.94)	$2.04 ($1.08–3.63)	$19.98 ($8.76–50.52)	$11.41 ($4.68–28.50)	$3.14 ($1.87–5.04)	$1.79 ($1.04–2.98)

[a] LI: Gross national income (GNI) per capita of $1,135 or less in 2024; LMI: GNI per capita $1,136 and $4,4915; UMI: GNI per capita of $4,496 and $13,935 (World Bank 2024) [12].

Note: AFR = African region; AMR = Region of the Americas; DTP3 = diphtheria-tetanus-pertussis third dose coverage; EMR = Eastern Mediterranean region; EUR = European region; GDP = gross domestic product; LIC = low-income; LMIC = lower middle-income; SEAR = Southeast Asian region; UMIC = upper middle-income; WPR = Western Pacific region.